A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains May 21, 2025 6:15 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock REGN 6 Comments ...

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

Biotech company Regeneron to buy bankrupt 23andMe for $256M Regeneron will use trove of 23andMe genetic data to develop medical advances.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.